Computational Cancer Pharmacologist | Postdoctoral Researcher at UNC Chapel Hill
Joined February 2018
- Tweets 330
- Following 434
- Followers 258
- Likes 1,956
34 Photos and videos
Pinned Tweet
14 Dec 2021
I've developed a model of combination chemotherapy and trained it on DLBCL trials. The ultimate test of my model is to predict new trial results, so I predicted the results of the POLARIX trial. Today I got to check the predictions, and they were right!
bit.ly/3yuf0MC
1
8
20
Dr. Amy Pomeroy retweeted
17 May 2025
'Less is more' maintenance therapy in #MultipleMyeloma!
Triplets→ASCT→3yr Len → D/C if MRD-neg (NGF PET/CT-neg)
Results: 3yr PFS ~93%, TFS ~75% *Treatment initiated for MRD resurgence
Based on @bdermanmd 's MRD2STOP this data: I'm comfortable stopping Len in standard-risk MRD-neg patients at 3yrs!
However, with quad induction MRD-neg 10^-6 by NGS, do we even need 3yrs of Len? As @End_myeloma reminds us, Len maintenance was built on the backbone of doublets!
tinyurl.com/8thww4sz
4
21
91
4,905
Dr. Amy Pomeroy retweeted
3 May 2025
A very well-written and thoughtful piece from Itai Yanai and Martin Lercher, with a nice visual showing how we “trim the tree” of the process, for publication.
On a related note, I’d like to see more Math Onco papers show the discovery process within papers — e.g. the process of model selection!
1
4
23
1,256
Dr. Amy Pomeroy retweeted
28 Apr 2025
i'm just a senior postdoc, standing in front of a career that i have worked really hard for, asking higher education in the united states to not completely implode in front of my eyes before i even get a chance to say the words 'my lab studies'
24
118
1,720
141,251
Dr. Amy Pomeroy retweeted
10 Apr 2025
Congratulations @ac_palmer @AmyEPomeroy !!! Fantastic to see this work out!
1
3
104
Dr. Amy Pomeroy retweeted
9 Apr 2025
New paper by @AmyEPomeroy!
A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma
Out now in Blood Cancer Discovery @BCD_AACR
doi.org/10.1158/2643-3230.BC…
#mathonc #lymsm #BloodCancer
1/n
7
9
36
2,581
Dr. Amy Pomeroy retweeted
7 Mar 2025
First author Amy Pomeroy presents her recently published work in Blood Cancer Discovery: A model of curative combination therapy for lymphoma by @amyEpomeroy and @ac_palmer.
Read the article: brnw.ch/21wRb8A
4
5
422
Dr. Amy Pomeroy retweeted
10 Feb 2025
Dr. Amy Pomeroy @AmyEPomeroy is up next in our postdoc spotlight session telling us about their work on mechanistic modeling of combination therapy
1
3
6
208
Dr. Amy Pomeroy retweeted
13 Nov 2024
New de-novo TCR design preprint from @DhuviKarthikey1 just dropped:
TCR-TRANSLATE: Conditional Generation of Real Antigen Specific T-cell Receptor Sequences
biorxiv.org/content/10.1101/…
1
19
96
9,240
Dr. Amy Pomeroy retweeted
5 Sep 2024
Kudos to @brian_rini for accurately describing the effects of combination therapies :)
5 Sep 2024
Thank you @TIME for highlighting our work in Kidney Cancer at @DanaFarber and @DanaFarber_GU
time.com/7018184/kidney-canc…
1
6
20
24,726
Dr. Amy Pomeroy retweeted
3 Jun 2024
📌 Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR , HER2-, node-positive, high-risk early breast cancer (EBC). Great talk by @LoiSher @OncoAlert #ASCO24 #BreastCancer
✔️the largest study
➡️8% positive for ctDNA at baseline
➡️ ctDNA detection was highly prognostic of worse outcomes, particularly for patients who were persistently positive
1
15
26
6,842
Dr. Amy Pomeroy retweeted
27 May 2024
Common Sense Oncology chapter is now live in ASCO Ed Book. Check it out.
ascopubs.org/doi/pdf/10.1200…
We also have a @csoncol session at #ASCO24 Monday morning 8AM!
2
27
77
22,297
23 May 2024
The UNC System has been doing DEI for as long as I can remember. North Carolina is a diverse state with multiple metropolitan counties (Wake, Mecklenburg, etc.) and many more rural counties (Edgecombe, Wataguga, etc.). Enrollment at UNC reflects that diversity.
1
1
1
266
23 May 2024
Example: In the same biology class you will find two students: one took AP chemistry and the other came from a school that didn't have a chemistry teacher. Both deserved to be there but the latter would have been excluded without DEI initiatives (and inclusive teaching practices)
1
59
23 May 2024
To make sure that the university represents the entire state we need programs that represent other underrepresented populations. The UNC System has eliminated the current mechanism to support diversity at our institutions. That doesn't mean we stop doing the work.
1
91
In the ALINA trial of adjuvant treatment for patients with resected ALK-positive non–small-cell lung cancer, disease-free survival at 2 years was 93.6% with the ALK inhibitor alectinib & 63.7% with standard chemotherapy. Full results & Research Summary: nej.md/3VUzf3M
ALT Top: Illustration of a patient with ALK-positive non–small-cell lung cancer and two treatments assigned during the ALINA trial: oral alectinib (600 mg twice daily) for 24 months or four 21-day cycles of intravenous platinum-based chemotherapy. Bottom: A graph showing that alectinib therapy was associated with a lower risk of disease recurrence or death than chemotherapy.
62
193
35,341
Dr. Amy Pomeroy retweeted
15 Apr 2024
Positive OS readout of STARGLO: glofit-GemOx vs R-GemOx in transplant ineligible R/R DLBCL
Will be exciting to see the full results
@mike_dickinson1
15 Apr 2024
#Breaking: Today we announced our CD20xCD3 bispecific antibody in combination with chemotherapy met its primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell #lymphoma, or #DLBCL. Learn more: gene.com/media/press-release…
3
15
32
7,735
Dr. Amy Pomeroy retweeted
10 Apr 2024
Exciting News! A new video capturing the mission of UNC's Computational Medicine Program. Catch the full video at KathASK Films on YouTube or simply click the following link for direct access: youtube.com/watch?v=YI8nHbmX… #PurvisLab #ComputationalMedicine #UNCSchoolOfMedicine
1
5
400